Constellation Brands Inc (NYSE: STZ - Get Free Report) has earned an average rating of "Hold" from the twenty-eight research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, thirteen have assigned a buy recommendation and one has
Constellation Brands is currently an undervalued Consumer Staples giant. It's seeing stabilizing volumes and has a solid growth runway through increased distribution and growing brands. Investors could see potentially strong total returns from the current depressed share price valuation and from dividends and buybacks.
Constellation Brands is reiterated as a Buy following a double-beat Q3 FY26 earnings report, despite ongoing macro headwinds. STZ's premium brand portfolio and strong financials support long-term upside, even as near-term consumer weakness and political risks persist. Management lowered FY26 EPS guidance but maintains a $1.35B FCF outlook, with significant shareholder returns through dividends and buybacks.
Constellation Brands, Inc. reported a double beat in Q3. Revenues declined less than expected, and margins were very resilient. STZ gained market share. The focus is on a weak alcoholic beverage industry. A secular decline in consumption continues to weigh on STZ, making capacity investment commitments concerning. I estimate STZ stock to have a fair value of $157.6.
Here are some of the major companies whose stocks moved on the week's news.
After a disastrous 2025, shares of beer giant Constellation Brands NYSE: STZ are starting 2026 off on a very positive note. To the chagrin of Berkshire Hathaway NYSE: BRK.B, Constellation Brands delivered a total return of -36% last year.
Release Date: January 08, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Constellation
The Corona distributor posted better-than-expected results in its third-quarter earnings report. Sales and profits still fell.
Shares of beverage company Constellation Brands (NYSE: STZ) are trading higher Thursday after the company beat third-quarter analyst estimates for revenue and earnings per share. An analyst sees the strong results as a good start to 2026 for several reasons.
Constellation Brands, Inc. (STZ) Q3 2026 Earnings Call Transcript
Constellation Brands Inc (NYSE:STZ) shares added more than 4% after the global alcohol producer and marketer's fiscal third quarter earnings topped analyst expectations despite declines in sales and operating income. The company posted net sales of $2.22 billion, down 10% from the prior year, while comparable net sales fell 2%.
Constellation Brands (STZ) reported impressive earnings and revenue for Q3 FY26, despite challenges in the alcoholic beverage market. Following the release, the
Constellation Brands executives said on Thursday beer sales could remain volatile and under pressure as economic uncertainty and high unemployment among Hispanic consumers, its core customer base, continue to weigh on spending.
Constellation Brands Inc (NYSE:STZ) shares are up 4.2% to trade at $146.41 at last check, after beating profit and revenue estimates for the fiscal third quarter.
STZ beat Q3 estimates despite sales and earnings declines, as beer outperformed the industry and cash flow supported dividends and buybacks.
Constellation Brands (STZ), parent company of Modelo and Corona, served an earnings win that lifted the stock Thursday morning. Even as demand improved, Diane King Hall says net sales still declined.
Stock futures pointed lower Thursday, a day after the benchmark S&P 500 and blue-chip Dow Jones Industrial Average set fresh all-time highs before retreating.
Stock futures are pointed lower this morning, despite a recovery in defense stocks and a slew of fresh data
Stock News Trump targets Wall Street homebuying: President Trump proposed banning large institutional investors from purchasing single-family homes, sending sha
Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more